Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma-Reference-Cited by-同舟云学术

Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma

Published:2024-02-23 Issue:4 Volume:47 Page:1277-1294
ISSN:2211-3428
Container-title:Cellular Oncology
language:en
Short-container-title:Cell Oncol.

Author:

Liu Tingyu,Yue Xin,Chen Xue,Yan Ru,Wu Chong,Li Yunzhi,Bu Xianzhang,Han Hui,Liu Ran-Yi

Funder

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

The Enterprise United Foundation of Guangdong Province

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13402-024-00927-9.pdf

Reference42 articles.

1. B. Shuch, A. Amin, A.J. Armstrong, J.N. Eble, V. Ficarra, A. Lopez-Beltran et al., Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Europ. Urol. 67, 85–97 (2015). https://doi.org/10.1016/j.eururo.2014.04.029

2. J.S. Lam, J.T. Leppert, A.S. Belldegrun, R.A. Figlin, Novel approaches in the therapy of metastatic renal cell carcinoma. World J. Urol. 23, 202–212 (2005). https://doi.org/10.1007/s00345-004-0466-0

3. N.K. Janzen, H.L. Kim, R.A. Figlin, A.S. Belldegrun, Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urologic Clini. North Am. 30, 843–852 (2003). https://doi.org/10.1016/s0094-0143(03)00056-9

4. A.M. Molina, X. Lin, B. Korytowsky, E. Matczak, M.J. Lechuga, R. Wiltshire et al., Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur. J. Cancer 50, 351–358 (2014). https://doi.org/10.1016/j.ejca.2013.08.021

5. S. Bracarda, R. Iacovelli, L. Boni, M. Rizzo, L. Derosa, M. Rossi et al., Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann. Oncol. 26, 2107–2113 (2015). https://doi.org/10.1093/annonc/mdv315